You are here

Article Text

Article menu
Download PDFPDF
PostScript
Letter
Off-label use of paracetamol in managing patent ductus arteriosus across neonatal intensive care units in the UK
  1. Arindam Mukherjee,
  2. Vishal Jadhav,
  3. Anupam Gupta
  1. Department of Neonatology, Manchester University NHS Foundation Trust, Manchester, UK
  1. Correspondence to Dr Arindam Mukherjee, St Mary's Hospital, Departmernt of Neonatology, Manchester University NHS Foundation Trust, Manchester M13 9WL, UK; arindam.mukherjee{at}mft.nhs.uk

https://doi.org/10.1136/archdischild-2020-320207

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    A haemodynamically significant patent ductus arteriosus (hsPDA) contributes significantly to mortality and morbidity in infants born earlier than 28 weeks’ gestation. Intravenous ibuprofen is the only licensed medication for medical management of patent ductus arteriosus (PDA) in the UK. It has its own side effects. There is emerging evidence to suggest that paracetamol may be a safer substitute to ibuprofen.

    We carried out a national telephone survey to ascertain the majority response on off-label use of paracetamol and explore areas of possible research in its use for managing hsPDA. The survey was conducted across 63 level 3 neonatal intensive care units …

    View Full Text

    Footnotes

    • Twitter @Arin Mukherjee

    • Contributors The project was conceived by AM. AG and AM prepared the questionnaire. Data were collected by VJ and coordinated by AM. Data were analysed by AM, AG and VJ. Write-up and critical analysis were done by AM and AG. All authors read and approved the final manuscript.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Patient consent for publication Not required.

    • Provenance and peer review Not commissioned; internally peer reviewed.